Literature DB >> 23002125

Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?

Vernon K Sondak1, Ragini Kudchadkar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23002125      PMCID： PMC3481887          DOI： 10.1634/theoncologist.2012-0368

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

Review 1.  Anti-CTLA-4 antibody adjuvant therapy in melanoma.

Authors:  Alexander M M Eggermont; Alessandro Testori; Michele Maio; Caroline Robert
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).

Authors:  Alexander M M Eggermont; Marna G Bouwhuis; Wim H Kruit; Alessandro Testori; Timo ten Hagen; Antoine Yver; Christine Xu
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-21       Impact factor: 3.333

3.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Authors:  Alexander M M Eggermont; Stefan Suciu; Alessandro Testori; Wim H Kruit; Jeremy Marsden; Cornelis J Punt; Mario Santinami; François Salès; Dirk Schadendorf; Poulam Patel; Reinhard Dummer; Caroline Robert; Ulrich Keilholz; Antoine Yver; Alan Spatz
Journal:  Eur J Cancer       Date:  2011-11-05       Impact factor: 9.162

4.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro Testori; Wim Kruit; Cornelis J A Punt; Michelle Delauney; François Sales; Gerard Groenewegen; Dirk J Ruiter; Izabella Jagiello; Konstantin Stoitchkov; Ulrich Keilholz; Danielle Lienard
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

5.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

6.  U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Authors:  Thomas M Herndon; Suzanne G Demko; Xiaoping Jiang; Kun He; Joseph E Gootenberg; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2012-09-21

7.  Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.

Authors:  Axel Hauschild; Michael Weichenthal; Knuth Rass; Ruthild Linse; Carola Berking; Jörg Böttjer; Thomas Vogt; Konstanze Spieth; Thomas Eigentler; Norbert H Brockmeyer; Annette Stein; Helmut Näher; Dirk Schadendorf; Peter Mohr; Martin Kaatz; Michael Tronnier; Rüdiger Hein; Gerold Schuler; Friederike Egberts; Claus Garbe
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

8.  Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Authors:  A I Daud; C Xu; W-J Hwu; P Urbas; S Andrews; N E Papadopoulos; L C Floren; A Yver; R C Deconti; V K Sondak
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-28       Impact factor: 3.333
  8 in total
  4 in total

Review 1.  Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.

Authors:  Yi-Wen Huang; Albert Qin; Chan-Yen Tsai; Pei-Jer Chen
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 2.  Revisiting the melanomagenic pathways and current therapeutic approaches.

Authors:  Pavan Kumar Dhanyamraju; Solomon Rotimi; Priyanjali Bhattacharya; Trupti N Patel
Journal:  Mol Biol Rep       Date:  2022-04-10       Impact factor: 2.742

3.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Authors:  Stefan S Bielack; Sigbjørn Smeland; Jeremy S Whelan; Neyssa Marina; Gordana Jovic; Jane M Hook; Mark D Krailo; Mark Gebhardt; Zsuzsanna Pápai; James Meyer; Helen Nadel; R Lor Randall; Claudia Deffenbaugh; Rajaram Nagarajan; Bernadette Brennan; G Douglas Letson; Lisa A Teot; Allen Goorin; Daniel Baumhoer; Leo Kager; Mathias Werner; Ching C Lau; Kirsten Sundby Hall; Hans Gelderblom; Paul Meyers; Richard Gorlick; Reinhard Windhager; Knut Helmke; Mikael Eriksson; Peter M Hoogerbrugge; Paula Schomberg; Per-Ulf Tunn; Thomas Kühne; Heribert Jürgens; Henk van den Berg; Tom Böhling; Susan Picton; Marleen Renard; Peter Reichardt; Joachim Gerss; Trude Butterfass-Bahloul; Carol Morris; Pancras C W Hogendoorn; Beatrice Seddon; Gabriele Calaminus; Maria Michelagnoli; Catharina Dhooge; Matthew R Sydes; Mark Bernstein
Journal:  J Clin Oncol       Date:  2015-06-01       Impact factor: 44.544

Review 4.  Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.

Authors:  Siddhartha Sood; Rahul Jayachandiran; Siyaram Pandey
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.